← All trials
NCT01784549
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2012
- Primary completion
- Oct 1, 2015
- Completion date
- Dec 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of GenoaLead sponsor
- University of GenoaOverall official - principal investigator
- Azienda Ospedaliera San Gerardo di MonzaCollaborator
- Ospedale Santa Croce-Carle CuneoCollaborator
- Azienda Ospedaliera S. Maria della MisericordiaCollaborator
- Azienda Ospedaliera San Camillo ForlaniniCollaborator
- Azienda Ospedaliera San Giovanni BattistaCollaborator
- University of VeronaCollaborator
- Istituto Tumori Giovanni Paolo II, BARICollaborator
- Azienda Ospedaliera Santa Maria Degli AngeliCollaborator
- Azienda Sanitaria Locale n.2 SavoneseCollaborator
- ASL TO4, ChivassoCollaborator
- Azienda Ospedaliera Sant'Andrea, RomaCollaborator
- Azienda Ospedaliera Spedali Riuniti di Livorno, LivornoCollaborator
- University of CagliariCollaborator
- University of GenoaReponsible party - principal investigator
- Azienda Ospedaliera Ospedale Civile di LegnanoCollaborator
- Istituto Clinico Humanitas - Rozzano (MI), ItalyCollaborator
- University of Campania Luigi VanvitelliCollaborator
- Azienda Provinciale per i Servizi Sanitari della Provincia Autonoma di TrentoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.